Wall Street analysts predict that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will post sales of $286.31 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Ionis Pharmaceuticals’ earnings. The highest sales estimate is $332.40 million and the lowest is $230.30 million. Ionis Pharmaceuticals posted sales of $144.42 million in the same quarter last year, which suggests a positive year-over-year growth rate of 98.2%. The business is scheduled to report its next quarterly earnings results on Friday, May 3rd.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year sales of $760.52 million for the current financial year, with estimates ranging from $727.87 million to $822.00 million. For the next fiscal year, analysts forecast that the company will post sales of $912.73 million, with estimates ranging from $595.60 million to $1.74 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $2.20. The firm had revenue of $192.00 million during the quarter, compared to the consensus estimate of $159.59 million. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) EPS.
Shares of NASDAQ IONS traded down $1.86 during trading hours on Thursday, hitting $83.76. The company had a trading volume of 799,498 shares, compared to its average volume of 1,032,840. The company has a market cap of $11.85 billion, a PE ratio of 28.30 and a beta of 2.42. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53. Ionis Pharmaceuticals has a 1-year low of $39.07 and a 1-year high of $86.58.
In related news, Chairman Stanley T. Crooke sold 77,000 shares of the stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $60.77, for a total value of $4,679,290.00. Following the sale, the chairman now owns 109,634 shares in the company, valued at approximately $6,662,458.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Patrick R. O’neil sold 19,600 shares of the stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $59.25, for a total value of $1,161,300.00. Following the completion of the sale, the senior vice president now owns 23,673 shares in the company, valued at approximately $1,402,625.25. The disclosure for this sale can be found here. In the last three months, insiders sold 339,205 shares of company stock valued at $24,034,607. 2.44% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Daiwa Securities Group Inc. raised its stake in Ionis Pharmaceuticals by 29.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after acquiring an additional 200 shares during the period. Keybank National Association OH increased its position in Ionis Pharmaceuticals by 1.2% during the 4th quarter. Keybank National Association OH now owns 21,606 shares of the company’s stock worth $1,168,000 after buying an additional 250 shares during the period. Brown Advisory Securities LLC increased its position in Ionis Pharmaceuticals by 4.7% during the 4th quarter. Brown Advisory Securities LLC now owns 6,151 shares of the company’s stock worth $330,000 after buying an additional 276 shares during the period. Huntington National Bank increased its position in Ionis Pharmaceuticals by 159.3% during the 4th quarter. Huntington National Bank now owns 638 shares of the company’s stock worth $34,000 after buying an additional 392 shares during the period. Finally, ETF Managers Group LLC increased its position in Ionis Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 2,956 shares of the company’s stock worth $160,000 after buying an additional 402 shares during the period. Institutional investors and hedge funds own 85.05% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Recommended Story: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.